Piceatannol Inhibits Akt Activation, Induces G2/M Phase Arrest and Mitochondrial Apoptosis and Augments Cisplatin Efficacy in U2OS Osteosarcoma Cells

Zijuan Li1,2, Rong Ma2, Muhammad Khan3*, Chenchen Liu2, Xiaolin Cui2 and Yongming Li1,2*

1Institute of Traditional Chinese Medicines, Nanjing University of Chinese Medicine, Nanjing 210023, P. R. China

2College of Basic Medical Sciences, Dalian Medical University, Dalian 116044, P.R. China

3Department of Zoology, University of the Punjab, Quaid-e-Azam Campus Lahore 54590, Pakistan

Zijuan Li and Rong Ma contributed equally to this work.

ABSTRACT

Piceatannol (3,3′,4,5′-tetrahydroxy-trans-stilbene), a naturally occurring analog of resveratrol has been shown to exhibit anticancer activity in various human cancer cells. However, the anticancer mechanism of piceatannol is not well studied. In the meantime, cisplatin (CDDP) is the first line treatment for some tumors. The present study was aimed to explore the cellular targets and anticancer mechanism of piceatannol in human osteosarcoma U2OS cells. Cell proliferation was measured using CCK-8 assay and colony forming assay. Flow cytometry was used to determine apoptosis and cell cycle profile. Western blot was used to measure the expression of various proteins. The data demonstrated that piceatannol inhibited growth and induced G2/M phase arrest and apoptosis. Further studies showed that piceatannol induces mitochondrial apoptosis as shown by Bcl-2 family proteins modulation. Finally, piceatannol significantly enhanced apoptotic efficacy of CDDP in U2OS cells. On the basis of our findings, piceatannol is a promising anticancer agent which could be developed into lead for osteosarcoma treatment as a single agent or in combination with CDDP.

Article Information

Received 15 July 2019

Revised 01 September 2019

Accepted 14 September 2019

Available online 19 September 2019

Authors’ Contribution

YL designed the study. ZL and RM performed experiments. CL and XC assisted in experimental work. The manuscript was drafted by ZL. MK and YL analyzed the data and proofread the manuscript.

Key words

Piceatannol, CDDP, Osteosarcoma, Apoptosis, Mitochondria

DOI: http://dx.doi.org/10.17582/journal.pjz/2019.51.6.2337.2344

* Corresponding author: liyongming1979@sina.com; khan_zoologist@ymail.com

0030-9923/2019/0006-2337$ 9.00/0

Copyright 2019 Zoological Society of Pakistan

INTRODUCTION

Human Osteosarcoma is the most commonly diagnosed malignant bone tumor, which mainly affects adolescents and young adults (Al Qahtani et al., 2015; Tan et al., 2006). Although the combination of modern surgery and systemic chemotherapy has improved osteosarcoma treatment dramatically, no substantial change in survival has been seen over the past 20 years (Akiyama et al., 2008). Therefore, to improve the survival of osteosarcoma patients, it is imperative to explore novel osteosarcoma therapies.

CDDP, a platinum-based alkylating agent is an effective drug for the treatment of various human cancers including osteosarcoma (Lamplot et al., 2013; Sasaoka et al., 2018). The prominent anticancer effects of CDDP are associated with induction of oxidative stress, DNA damage and apoptosis (Ghosh, 2019). The emergence of drug resistance has limited the use of CDDP in the successful treatment of various cancers including osteosarcoma (Fraser et al., 2003; Farrand et al., 2013). Therefore, it is important to explore new strategies, such as combination of natural products with clinical cancer drugs to overcome drug resistance.

As the ultimate goal of translational medicine is to develop new treatment strategies and to improve health across populations (Polese and Capunzo., 2013), more and more researchers are focusing to find novel combinations of natural compounds with cancer clinical drugs. Piceatannol, also known as 3-hydroxy resveratrolis, is a naturally occuring analog of the cancer chemopreventive agent resveratrol (trans-3,5,4’-trihydroxystilbene) (Fig. 1A), a natural antioxidant and a naturally occurring polyphenol present in the skins of grapes, red wine, and other foods (Ko et al., 2012; Kwon et al., 2012; Wolter et al., 2002). Piceatannol is used in traditional herbal medicine and folk medicine to treat cancer, tumors and warts (Wolter et al., 2002).

To date, piceatannol has been known to exhibit anticancer, anti-inflammatory and cardio-protective properties. Piceatannol has been reported to have antitumor effects in various types of human cancer, including breast cancer, bladder cancer, prostate cancer and lung cancer (Dhanapal and Balaraman Ravindrran., 2018; Ko et al., 2012; Kwon et al., 2012; Kuo and Hsu, 2008). Recently, the anti-angiogenic and anti-metastatic effects of piceatannol have been reported (Kim and Ma, 2019). The effects of piceatannol in osteosarcoma cells are not yet fully understood. In this study, we investigated the anticancer activity of piceatannol and its underlying mechanism in osteosarcoma using U2OS cells. Furthermore, we have evaluated the chemosensitizing effects of piceatannol.

 

MATERIALS AND METHODS

Antibodies and reagents

Piceatannol (Fig. 1B) was purchased from Selleck Chemicals (Cat: S3026, Shanghai, China) with purity >99% as determined by HPLC (Fig. 1C). The antibodies against Bax (sc-493), Bak (sc-832), Bcl-2 (sc-492), Cleaved PARP (sc-56196), P21 (sc-397), P27 (sc-1641), cyclin A (sc-596), cyclin B (sc-166210), CDC2 (sc-54) and cyclin D1 (sc-20044) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA); antibodies against γ-H2AX (9718p), Cleaved caspase-3 (9664), p-AKT (13038p), AKT (4691p), P-GSK-3β (5558p), P-C-Raf (9421p), Lc3B (2775s), p-CDC2 (4539) and P-PTEN (9551p) were purchased from Cell Signaling Technology (Danvers, MA, USA); antibodies against β-actin (66009-1-lg), GAPDH (10494-1-AP), p53(10442-1-AP) and CDK3 (55103-1-AP) were purchased from Proteintech (Wuhan, China).

Dulbecco’s Modified Eagle’s Medium (DMEM), fatal bovine serum (FBS), cell counting kit-8 (CCK-8) and propidium iodide (PI) were obtained from Sigma-Aldrich (St. Louis, MO, USA). Crystal violet solution and Annexin V/PI double staining apoptosis assay kit were obtained from Beyotime institute of Biotechnology (Heimen, Jiangsu, China).

Cell line and culture

Human U2OS Osteosarcoma cells were obtained from ATCC (Manssas, VA, USA) and cultured in DMEM medium supplemented with 10% FBS at 37°C with 5% CO2 in humidified atmosphere. The medium was replaced for every 2-3 days. Cells were treated with various concentrations (0, 20, 40, 60, 80 μM) of piceatannol in culture medium.

 

Cell counting kit-8 (CCK-8) assay

Cell viability was measured using CCK-8 assay kit according to manufacturer’s instructions (Sigma-Aldrich). In this assay, WST-8 (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt) is used instead of other tetrazolium dyes such as MTT, XTT or MTS. Live cells convert WST-8 into an orange formazan product which is soluble in cell culture medium. The amount of formazan produced is directly proportional to the number of living cells. Briefly, U2OS cells at 1 x 103 cells/well in 100μL complete culture medium were seeded in 96-well plates. After culturing for 24 h, the medium was replaced with fresh DMEM containing various concentration of drug. Then, 10µL of CCK-8 solution was added to each well for another 4 h and the absorbance at 450 nm was measured by Synergy neo HTS multimode microplate reader (Bio Tec).

Cell count

Determination of cell number was carried out by flow cytometry. U2OS cells were plated at a density of 1×104 cells/well in 12-well plates. Cells were treated with various concentrations of piceatannol for 24 h. Following drug treatment, the cell numbers was counted by flow cytometry.

Colony forming assay

The anti-proliferative activity of drug was also determined by colony forming assay. Cells were seeded into 6 well cell culture plates and treated with different concentrations of drug for 24 h. The drug containing medium was replaced with fresh culture medium and cells were allowed to grow for 10 days. On appearance of colonies, cells were fixed with 4% paraformaldehyde (PFA) for 20 min and stained with crystal violet solution for 30 min and photographed.

Cell cycle analysis

Cell cycle distribution was analyzed using BD Accuri C6 Flow Cytometer. Treated and untreated cells were collected and fixed in 70% ethanol overnight at 4°C. After that, cells were centrifuged at 1200 rmp for 5 min. The cells pellet was resuspended in 100 µg/mL RNase A and 50 µg/mL PI at 37°C for 30 min in the dark. The samples were analyzed by flow cytometry for analysis of cell cycle profile.

Apoptosis assay

Apoptosis was determined using Annexin V-FITC/PI apoptosis detection kit. Briefly, the cells were harvested and washed with cold PBS and incubated with 500µL binding buffer. After that, 5µL Annexin V-FITC and 10µL PI were added to the cells. In addition, the cells were incubated for 15 min in the dark. Cell apoptosis was analyzed with at least 20,000 cells for each measurement by BD Accuri C6 flow cytometer.

Western blot analysis

Cells were lysed in Radioimmunoprecipitation assay (RIPA) buffer (1% NP40, 0.5% sodium deoxycholate, 0.1% SDS in PBS). Complete protease inhibitor cocktail (Roche) was added to lysis buffer before use. Protein concentration was determined by detergent-compatible protein assay (Bio-Rad). Protein samples were subjected to SDS-PAGE and transferred to nitrocellulose membrane. The membrane was blocked with 5% nonfat milk in PBS for 15 min and incubated with primary antibodies Bax (1:500), Bak (1:500), Bcl-2 (1:500), Cleaved PARP (1:500), P21 (1:500), P27 (1:500), cyclin A (1:500), cyclin B (1:500), CDC2 (1:500), cyclin D1 (1:500), γ-H2AX (1:1000), Cleaved caspase-3 (1:1000), p-AKT (1:1000), AKT (1:1000), P-GSK-3β (1:1000), p-C-Raf (1:1000), Lc3B (1:1000), p-CDC2 (1:1000), p-PTEN (1:1000), β-actin (1:1000), GAPDH (1:1000), p53(1:1000) and CDK3 (1:1000) overnight at 4°C. After washing the membranes with PBST three times for 5 min, the membrane was incubated with appropriate horseradish peroxidase (HRP)-conjugated secondary antibody (1:5000) for one hour at room temperature. The membranes were washed three times again; signals were developed with enhanced chemiluminescence reagents (Pierce) and exposed to X-ray films. Image digitization and quantification were done with Image Lab software. GAPDH and/or Beta-actin were used as loading control. The bars in graph represent the relative density of the bands normalized to GAPDH and/or β-actin from three repeated experiments.

Statistical analysis

Data are expressed as Mean ± S.D from three independent experiments. Student t-test was used to compare means. *P<0.05, **p<0.01, and ***p<0.001 indicate statistical significant difference compared with control group.

 

RESULTS

Effects of piceatannol on the inhibition of cell growth

To determine the effect of piceatannol on the growth of U2OS cells, we incubated the U2OS cells with different doses of piceatannol for 72 h and cell proliferation was evaluated by Cell Counting Kit-8 (CCK-8) assay. As shown in Figure 2A, piceatannol inhibited the growth of cells in a dose-dependent manner with IC50 value around 46.53 μΜ. We also counted the number of cells using flow cytometry. As shown in Figure 2B, the number of cells was significantly lower in treatment groups as compared to control group.

 

To better understand the inhibitory effect of piceatannol on cell proliferation, anti -proliferative nature of piceatannol was investigated by colony forming assay. We found that piceatannol inhibited colony formation in a dose-dependent manner as shown in Figure 2C. Overall, these results indicated that piceatannol has an anti-proliferative activity against U2OS cells.

Piceatannol induces morphological changes and cell death in U2OS cells

To determine whether piceatannol exerts any cytotoxic effects, we observed cell morphological changes. U2OS cells were incubated with 0, 20, 40 and 80 μΜ piceatannol for 24 h and cellular morphology was observed under phase-contrast microscope. Piceatannol induces severe morphological changes including the reduction in the total number of cells and loss of cellular geometry (Fig. 3A). In addition to cell morphological changes, we also examined nuclear morphological changes using Hoechst 33258 staining. Piceatannol treatment induced DNA fragmentation in U2OS cells in a dose-dependent manner, as shown in Figure 3B.

 

 

Piceatannol effectively induces apoptosis and suppresses PI3K/AKT pathway in U2OS cells.

The effects of piceatannol on U2OS cells apoptosis was evaluated by Hoechst 33258 staining and Annexin V/PI double staining kit. As shown in Figure 3B, piceatannol induces DNA fragmentation in U2OS cells in a dose-dependent manner. The apoptotic effect of piceatannol was further verified by flow cytometry analysis. U2OS cells were treated with piceatannol and stained with Annexin V-FITC and PI for the analysis of apoptosis. The data showed that piceatannol induces apoptosis in U2OS cells in a dose-dependent manner (Fig. 4A). To further confirm the induction of apoptosis by piceatannol, we measured the expression of cleaved caspase-3 and cleaved poly (ADP-ribose) polymerase (PARP) which are considered the markers of apoptotic cell death. The Western blot analysis showed that the expressions of cleaved caspase-3 and cleaved-PARP were increased in piceatannol-treated groups (Fig. 4B). Since piceatannol induced DNA damage in U2OS cells in a dose-dependent manner, we measured the expression of Phosphorylated histone H2AX (ɣH2AX) which is an early marker of DNA damage (Kuo et al., 2008). We found an increase in the expression of ɣH2AX in piceatannol-treated cells (Fig. 4B). Next, we measured the expression of Bcl-2 family proteins. The data indicated that piceatannol up-regulated the expression of pro-apoptotic proteins bax and bak while down-regulated the expression of anti-apoptotic bcl-2 protein (Fig. 4B). Taken together, the data indicated that piceatannol triggered cell death in U2OS cells by inducing apoptosis, which was associated with the up-regulation of pro-apoptotic proteins and down-regulation of anti-apoptotic proteins. We also evaluated the effect of piceatannol on phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway. Our Western blot data showed that piceatannol effectively inhibits PI3K/AKT pathway as evident from decreased expression of p-AKT and phosphorylated Glycogen synthase kinase-3 beta (p-GSK-3β) in U2OS cell (Fig. 4C).

 

Piceatannol induces G2/M phase arrest in U2OS cells

To determine whether piceatannol exerts any effect on the cell cycle progression of U2OS cells, the DNA contents at different phases of the cell cycle were analyzed by flow cytometry. Piceatannol increased cell number at G2/M phase in a dose-dependent manner accompanied by a decreased cell number at S and G0/G1 phases in U2OS cells (Fig. 5A). Furthermore, we detected the expression of various cell cycle-regulators including P53, P21, P27, cyclin A, cyclin B, cyclin D, cyclin-dependent kinase 1(cdc2), p-cdc2 and cyclin-dependent kinase-3 (cdk3). We found that piceatannol increased the expressions of p53, p21, p27, cyclin B and p-cdc2 while decreased the expressions of cyclin A, cyclin D1 and cdk3 (Fig. 5B).

 

Piceatannol enhances CDDP –induced apoptosis in U2OS cell

Next, we asked if piceatannol could enhance the efficacy of CDDP in U2OS cells. For this, we treated the cells with piceatannol (40 μΜ) and CDDP (20 μg/ml) individually or a combination of both for 24 h and measured apoptosis rates using flow cytometry analysis. As shown in Figure 6A, the rate of apoptosis in combine treatment of cells with piceatannol and CDDP was higher compared with either drug alone. These results were further confirmed by measuring the expressions of cleaved caspase-3, cleaved PARP and ɣH2AX (Fig. 6B). Taken together, these results indicated that piceatannol enhanced the effect of CDDP on apoptosis in U2OS cells.

 

DISCUSSION

Piceatannol, a naturally occurring polyphenol is an analog of resveratrol, a potent natural chemopreventive agent isolated from grapes (Wolter et al., 2002). Piceatannol has been reported to exhibit broad-spectrum anticancer activity in various human cancer cell lines (Seyed et al., 2016). However, till now no report is available on anticancer activity of piceatannol on osteosarcoma. The present study was conducted to evaluate the anticancer effects of piceatannol in osteosarcoma using U2OS cell line. Piceatannol inhibited the growth of U2OS osteosarcoma cells as evident from CCK-8 and colony formation assays. Apoptosis and cell cycle arrest are the main factors associated with cancer cell growth inhibition in response to chemotherapy (Khan et al., 2012a,b). Therefore, we determined apoptosis rate in U2OS cells in response to piceatannol treatment. The data demonstrated that piceatannol remarkably induced apoptotic cell death in a dose-dependent manner as evident from Annexin V/PI staining, Hoechst 33258 staining and cleavage of caspase-3 and PARP. The data is in agreement with other research reports indicating that piceatannol induces apoptosis in various other cancer cell lines (Seyed et al., 2016; Du et al., 2017). Bcl-2 family proteins are considered one of the most important players of apoptosis induction in a large number of human cancer cell lines (Khan et al., 2013; Khan et al., 2016). Therefore, we examined if piceatannol could modulate the expression of bcl-2 family proteins. We found that piceatannol up-regulated the expression of pro-apoptotic bax and bak while down-regulated the expression of anti-apoptotic bcl-2 protein. Similar results of piceatannol on apoptotic machinery have been reported by Kim et al., in human U937 leukemia cells (Kim et al., 2008).

Next we asked if picatannol could induce cell cycle arrest at a specific checkpoint. Therefore, we analyzed the cell cycle phase distribution profile of U2OS cells. The data showed that piceatannol arrested the cell cycle at G2/M phase. P53 being the major tumor suppressor protein plays vital role in G2/M phase arrest by activating its downstream target genes p21 and p27 (CDKs inhibitors). Cell cycle progression from G2 to M phase is mediated by cyclinB1/cdc2 complex. Cells with suppressed activity of this complex are arrested at G2 phase (Khan et al., 2011; Khan et al., 2012b). Here in this study, piceatannol increased the expression of p53, p21 and p27 and decreased the expression of cyclin A, cyclin D1 and cdk3. Piceatannol have been previously reported to induce cell cycle arrest at S and G1 phase in colorectal and prostate cancer cells, respectively (Lee et al., 2009; Wolter et al., 2002). This discrepancy in data might be the result of different cancer types.

PI3k/Akt is a survival pathway and is implicated in key cellular processes including cell proliferation, survival, migration and metabolism. This pathway is frequently overexpresses in various cancer cells and promotes cell survival by inhibiting apoptosis and is involved in cell cycle regulation by inhibiting GSK-3β through phosphorylation. Inhibition of PI3k/Akt signaling pathway plays vital role in cell growth inhibition, induction of apoptosis and cell cycle arrest (El-Deiry, 2001; Khan et al., 2015). To further explore the anticancer role of piceatannol, we examined its effects on PI3k/Akt signaling pathway. Piceatannol effectively inhibited this signaling pathway as could be seen from decreased phosphorylation of AKT and GSK-3β.

Development of drug resistance has limited the scope of chemotherapy in the successful treatment of cancer (Maryam et al., 2017). Exploring novel combination of natural bioactive compounds with clinical drugs is a rational approach to enhance the efficacy of existing clinical drugs. In the present study, we investigated the chemo-sensitizing effect of piceatannol. The data provided strong support for the additive effects of piceatannol in combination with CDDP in U2OS cells.

 

CONCLUSION

In conclusion, we have shown that piceatannol inhibits cells proliferation, induces intrinsic apoptosis and G2/M phase cell cycle arrest in U2OS osteosarcoma cells. Furthermore, we revealed that piceatannol increased the sensitivity of U2OS cells to CDDP via inducing apoptosis. Taken together, these results suggest that piceatannol is a promising natural compound for the treatment of human Osteosarcoma tumor. Further study is needed to explore the in-depth anticancer mechanism and validate its activity using in vivo animal models in order to develop it into a lead for osteosarcoma therapy.

 

ACKNOWLEDGEMENTS

This research work was supported by research grants from National Natural Science Foundation of China (Grant No:81672944 and 81402330).

 

Statement of conflict of interest

The authors declare no conflict of interests.

 

REFERENCES

Akiyama, T., Dass, C.R. and Choong, P.F., 2008. Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway. Mol. Cancer Ther., 7: 3461-3469. https://doi.org/10.1158/1535-7163.MCT-08-0530

AL Qahtani, D., AlSheddi, M. and Al-Sadhan, R., 2015. Epithelioid osteosarcoma of the Maxilla: A case report and review of the literature. Int. J. Surg. Pathol., l23: 495-499. https://doi.org/10.1177/1066896915591273

Dhanapal, J. and Balaraman, R.M., 2018. Chitosan/poly (lactic acid)-coated piceatannol nanoparticles exert an in vitro apoptosis activity on liver, lung and breast cancer cell lines. Artif. Cells Nanomed. Biotechnol., 46: 274-282. https://doi.org/10.1080/21691401.2017.1422130

Du, M., Zhang, Z. and Gao, T., 2017. Piceatannol induced apoptosis through up-regulation of microRNA-181a in melanoma cells. Biol. Res., 50: 36. https://doi.org/10.1186/s40659-017-0141-8

El-Deiry, W. S., 2001, Akt takes centre stage in cell-cycle deregulation. Nat. Cell Biol. 3:.

El-Deiry, W.S., 2001. Akt takes centre stage in cell-cycle deregulation. Nat. Cell. Biol., 3: E71-73.

Farrand, L., Byun, S., Kim, J.Y., Im-Aram, A., Lee, J., Lim, S., Lee, K.W., Suh, J.Y., Lee, H.J. and Tsang, B.K., 2013. Piceatannol enhances cisplatin sensitivity in ovarian cancer via modulation of p53, X-linked inhibitor of apoptosis protein (XIAP), and mitochondrial fission. J. biol. Chem., 288: 23740-23750. https://doi.org/10.1074/jbc.M113.487686

Fraser, M., Leung, B., Jahani-Asl, A., Yan, X., Thompson, W.E. and Tsang, B.K., 2003. Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reprod. Biol. Endocrinol., 1: 66. https://doi.org/10.1186/1477-7827-1-66

Ghosh, S., 2019. Cisplatin: The first metal based anticancer drug. Bioorg. Chem., 88: 102925. https://doi.org/10.1016/j.bioorg.2019.102925

Khan, M., Maryam, A., Zhang, H., Mehmood, T., Ma, T., 2016. Killing cancer with platycodin D through multiple mechanisms. J. Cell. mol. Med., 20: 389-402. https://doi.org/10.1111/jcmm.12749

Khan, M., Ding, C., Rasul, A., Yi, F., Li, T., Gao, H., Gao, R., Zhong, l., Zhang, K., Fang, X. and Ma, T., 2012a. Isoalantolactone induces reactive oxygen species mediated apoptosis in pancreatic carcinoma PANC-1cells. Int. J. biol. Sci., 8: 533-547. https://doi.org/10.7150/ijbs.3753

Khan, M., Li, T., Ahmad Khan, M.K., Rasul, A., Nawaz, F., Sun, M., Zheng, Y. and Ma, T., 2013. Alantolactone induces apoptosis in HepG2 cells through GSH depletion, inhibition of STAT3 activation, and mitochondrial dysfunction. BioMed. Res. Int., 2013: 719858. https://doi.org/10.1155/2013/719858

Khan, M., Maryam, A., Qazi, J.I. and Ma, T., 2015. Targeting Apoptosis and Multiple Maryam, A., Mehmood, T., Zhang, H., Li, Y., Khan, M., Ma, T., 2017. Alantolactone signaling pathways with Icariside II in Cancer Cells. Int. J. biol. Sci., 11: 1100-1112. https://doi.org/10.7150/ijbs.11595

Khan, M., Rasul, A., Yi, F., Zhong , L. and Ma, T., 2011. Jaceosidin induces p53- dependent G2/M phase arrest in U87 glioblastoma cells. Asian Pac. J. Can. Prev., 12: 3235-3238.

Khan, M., Zheng, B., Yi, F., Rasul, A., Gu, Z., Li, T., Gao, H., Qazi, J.I., Yang, H. and Ma, T., 2012b. Pseudolaric acid B induces caspase- dependent and caspase- independent apoptosis in u87 glioblastoma cells. Evid. Based Complement. Alternat. Med., 2012: 957568. https://doi.org/10.1155/2012/957568

Kim, A. and Ma, J.Y., 2019. Piceatannol-3-O-β-D-glucopyranoside (PG) exhibits in vitro anti-metastatic and anti-angiogenic activities in HT1080 malignant fibrosarcoma cells. Phytomedicine, 57: 95-104. https://doi.org/10.1016/j.phymed.2018.12.017

Kim, Y. H., Park, C., Lee, J.O., Kim, G.Y., Lee, W.H., Choi, Y.H. and Ryu, C.H., 2008. Induction of apoptosis by piceatannol in human leukemic U937 cells through down-regulation of Bcl-2 and activation of caspases. Oncol. Rep., 19: 961-967. https://doi.org/10.3892/or.19.4.961

Ko, H.S., Lee, H.J., Kim, S.H. and Lee, E.O., 2012. Piceatannol suppresses breast cancer cell invasion through the inhibition of MMP-9: involvement of PI3K/AKT and NF-kappaB pathways. J. Agric. Fd. Chem., 60: 4083-4089. https://doi.org/10.1021/jf205171g

Kuo, L.J. and Yang, L.X., 2008. Gamma H2AX- a novel biomarker for DNA double-stand breaks. In vivo, 22: 305-309.

Kuo, P.L. and Hsu, Y.L., 2008. The grape and wine constituent piceatannol inhibits proliferation of human bladder cancer cells via blocking cell cycle progression and inducing Fas/membrane bound Fas ligand-mediated apoptotic pathway. Mol. Nutr. Food Res., 52:408-18. https://doi.org/10.1002/mnfr.200700252

Kwon, G.T., Jung, J.I., Song, H.R., Woo, E.Y., Jun, J.G., Kim, J.K., Her, S. and Park, J.H., 2012. Piceatannol inhibits migration and invasion of prostate cancer cells: possible mediation by decreased interleukin-6 signaling. J. Nutr. Biochem., 23: 228-238. https://doi.org/10.1016/j.jnutbio.2010.11.019

Lamplot, J.D., Denduluri, S., Qin, J., Li, R., Liu, X., Zhang, H., Chen, X., Wang, N., Pratt, A., Shui, W., Luo, X., Nan, G., Deng, Z.L., Luo, J., Haydon, R.C., He, T.C. and Luu, H.H., 2013. The current and future therapies for human osteosarcoma. Curr. Cancer Ther. Rev., 9: 55-77. https://doi.org/10.2174/1573394711309010006

Lee, Y.M., Lim, D.Y., Cho, H.J., Seon, M.R., Kim, J.K., Lee, B.Y. and Park, G.H., 2009. Piceatannol, a natural stilbene from grapes, induces G1 cell cycle arrest in androgen-insensitive DU145 human prostate cancer cells via the inhibition of CDK activity. Cancer Lett., 285: 166-173. https://doi.org/10.1016/j.canlet.2009.05.011

Maryam, A., Mehmood, T., Zhang, H., Li, Y., Khan, M. and Ma, T., 2017. Alantolactone induces apoptosis, promotes STAT3 glutathionylation and enhances chemosensitivity of A549 lung adenocarcinoma cells to doxorubicin via oxidative stress. Sci. Rep., 7:6242. https://doi.org/10.1038/s41598-017-06535-y

Polese, F. and Capunzo, M., 2013. The determinants of translational medicine success - a managerial contribution. Transl. Med. UniSa., 6: 29–34.

Sasaoka, K., Kataoka, T., Kanzaki, N., Kobashi, Y., Sakoda, A., Ishimori, Y. and Yamaoka, K., 2018. Comparative effects of radon inhalation according to mouse strain and cisplatin dose in a cisplatin-induced renal damage model. Pakistan J. Zool., 50: 1157-1170. http://dx.doi.org/10.17582/journal.pjz/2018.50.3.1157.1170

Seyed, M.A., Jantan, I., Bukhari, S.N. and Vijayaraghavan, K., 2016. A comprehensive review on the chemotherapeutic potential of piceatannol for cancertreatment, with mechanistic insights. J. Agric. Fd. Chem., 64: 725-737. https://doi.org/10.1021/acs.jafc.5b05993

Tan, J.Z., Schlicht, S.M., Powell, G.J., Thomas, D., Slavin, J.L., Smith, P.J. and Choong, P.F., 2006. Multidisciplinary approach to diagnosis and management of osteosarcoma - a review of the St Vincent’s Hospital experience. Int. Semin. Surg. Oncol., 3: 38. https://doi.org/10.1186/1477-7800-3-38

Wolter, F., Clausnitzer, A., Akoglu, B. and Stein, J., 2002. Piceatannol, a natural analog of resveratrol, inhibits progression through the S phase of the cell cycle in colorectal cancer cell lines. J. Nutr., 132: 298-302. https://doi.org/10.1093/jn/132.2.298